Leticia Fernandes Barroso

Leticia Fernandes Barroso

Auto-generated profile, based on publicly available information

Leticia Fernandes Barroso

Faculty of Medicine, Catholic University of Brasília , Brasília

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 March 2026 in Dermatology and Therapy
Verified
Journal Article
Open access
PDF file
RSRodrigo R. de Sena
Rodrigo R. de Sena
KMKleyton de C Mesquita
Kleyton de C Mesquita
LBLetícia F. Barroso
Letícia F. Barroso
PCPaola B. E. Canabrava
Paola B. E. Canabrava
FZFernando Zanghelini
Fernando Zanghelini
Ciro Martins GomesCiro Martins Gomes
Ciro Martins Gomes
Introduction Recent trials with withdrawal arms in patients with psoriasis have highlighted the need for updated clinical guidance. The aim of this investigation was to compare the effects and safety of planned limited-time withdrawal versus continuous maintenance of interleukin (IL) inhibitors in patients with psoriasis. Methods On August 5, 2025, the following platforms were systematically searched: PubMed, Embase, Clarivate (Web of Science), Scopus, and Ovid. Titles and abstracts, followed by full-text articles, were independently screened by two reviewers, with any disagreements being resolved by a third reviewer. Certainty of evidence was evaluated via the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach. Network meta-analyses for the Psoriasis Area and Severity Index (PASI) 90 and PASI100 outcomes were performed. The risk ratio (RR) of relapse was ranked using the surface under the cumulative ranking curve (SUCRA) metric. Results A total of 7444 records were retrieved, 54 of which included data from 18 different trials. The data revealed a total of 2995 patients who were subjected to anti-IL withdrawal regimens that were eligible for comparison with anti-IL maintenance. For the PASI90 outcome, the network meta-regression, adjusted for a post-withdrawal follow-up duration of 40–48 weeks, indicated that bimekizumab demonstrated a RR for relapse (RR 5.36; 95% confidence interval (CI) 3.45–8.34; SUCRA 0.685) comparable to that of guselkumab (RR 7.45; 95% CI 4.97–11.19; SUCRA 0.412) and lower than that of ixekizumab (RR 17.45; 95% CI 10.22–29.80; SUCRA 0.006). No significant difference in adverse event rates was observed between the anti-IL withdrawal and maintenance groups. Conclusions Compared with continued treatment, planned withdrawal of anti-IL therapy is associated with a largely superior risk of relapse, without any reduction in the incidence of adverse events. Moreover, bimekizumab withdrawal demonstrated better outcomes than ixekizumab withdrawal did according to the PASI90 outcome. Study Registration This study was prospectively registered on PROSPERO (identification number CRD420251118724).

3 October 2026 in British Journal of Dermatology
Verified
Journal Article
Open access
JNJuliana Nakano
Juliana Nakano
LBLetícia Fernandes Barroso
Letícia Fernandes Barroso
KMKleyton de Carvalho Mesquita
Kleyton de Carvalho Mesquita
Ciro Martins GomesCiro Martins Gomes
Ciro Martins Gomes
JSJonathan Silverberg
Jonathan Silverberg
Background: Recent therapeutic advances have transformed the management of atopic dermatitis (AD). Medication withdrawal, dose reduction and dosing interval extension are sometimes necessary when managing AD. Objectives: To compare the effectiveness of withdrawal, dose reduction and dosing interval extension with that of continuation of systemic therapy in sustaining remission in patients with AD. Methods: A comprehensive search of PubMed, Embase, Web of Science and Scopus was conducted. Study selection was performed independently by two reviewers; discrepancies were resolved by a third reviewer. The risk of bias was evaluated using the Cochrane risk-of-bias tool for randomized trials (RoB 2) and the Risk of Bias in Nonrandomized Studies of Interventions (ROBINS-I) tool. The certainty of the evidence was determined in accordance with the GRADE framework. The primary outcome was defined as sustained clinical improvement, measured by a 75% reduction in the Eczema Area and Severity Index (EASI 75), which was assessed 16–52 weeks after treatment withdrawal, dose reduction or dosing interval extension. Risk ratios (RRs) were compared using a network meta-analysis (NMA). Results: After the initial search yielded 21 169 references, 89 reports representing 55 studies were included. Raw data analysis indicated that most active treatments showed comparable RRs for EASI 75 maintenance, whereas the discontinuation of oral therapies led to early relapses in AD activity. On the basis of 9 studies encompassing 26 pairwise comparisons and 2585 observations across 13 regimens, our NMA revealed that lebrikizumab withdrawal and dosing interval extension conferred a lower risk of EASI 75 response loss than withdrawal, dose reduction or dosing interval extension with other active therapies. A subgroup analysis also revealed that the maintenance of EASI 75 responses after placebo withdrawal or dosing interval extension was greatest for induction dosing with lebrikizumab. Conclusions: While the withdrawal of systemic therapy is recommended in certain circumstances, such as during vaccination and pregnancy, the evidence reveals an early risk of relapse following the withdrawal of oral treatments. In contrast, biologic therapies resulted in sustained remission rates, even after prolonged withdrawal or dosing interval extension periods. An author video to accompany this article is available online.

1 February 2024 in Research, Society and Development
Verified
Journal Article
Open access
PDF file
LOLiana Andrade Oliveira
Liana Andrade Oliveira
LOLarissa Albuquerque Oliveira
Larissa Albuquerque Oliveira
LBLeticia Fernandes Barroso
Leticia Fernandes Barroso
AMAlexis Galeno Matos
Alexis Galeno Matos
Uveitis is inflammation of the uveal tract. The main manifestations are ocular hyperemia, photophobia, ocular pain, blurred vision, irregular pupil and inflammatory nodules on the anterior surface of the iris. Currently, the treatment of uveitis is associated with the use of corticosteroids. Adalimumab (ADA) is a full-length human monoclonal antibody, which is involved in the intraocular inflammation cascade, being effective in suppressing uveitis, allowing a significant reduction in the immunosuppression burden and associated corticosteroid dosage. In this study, we performed a meta-analysis with the aim of evaluating the effectiveness of using ADA in the treatment of non-infectious intermediate and posterior uveitis and panuveitis. A systematic literature review study that addressed research published between 2016 and 2021. Our systematic review selected a total of 60 articles and, among these, 12 were used with different methodological approaches, with age groups and samples varied populations. Within our study, all 12 selected articles demonstrated, in general, a good efficacy and safety of biological therapy with ADA, mainly in combined therapy and aimed at the chronicity and refractoriness of the disease associated with evidence on a pattern of improvement in all or most of the outcomes assessed.